BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology

Contributed by: Business Wire

Logo

Business Wire logo

Images

BioLife offers a new solution for oral GLP-1 delivery
BioLife offers a new solution for oral GLP-1 delivery
Business Wire embedded0

Tags

Science
Other Science
Research
Pharmaceutical
General Health
Health
Diabetes
Clinical Trials
BioLife

More Like This

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

ACCESSWIRE logo

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1

Over 55,000 people already on Simple Online Healthcare's waitlist for UK's first, newly approved oral GLP-1

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

PR Newswire associated0

Lembas Emerges from Stealth with Breakthrough Discovery in Natural GLP-1 for Weight Management

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions